Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05197881 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

Study acronym: ARTIA-Cervix
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: May 2026 to Sep 2028
    • Study completion date: May 2028 to Sep 2030
    • Site details revised at 1 of 5 sites
    v8
  2. Study sites: 4 to 5v7
  3. Primary completion date: May 2024 to May 2026v6 Show 4 more changesShow less
    • Study sites: 3 to 4
    • Study completion date: May 2026 to May 2028
    • Eligibility criteria expanded, about 61 words
    • Secondary endpoints: 8 to 9
  4. Site details revised at 1 of 3 sitesv5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 1 to 3
    • Primary completion date: Apr 2024 to May 2024
    • Study completion date: Apr 2026 to May 2026
    • Start date changed from estimate of Apr 2022 to May 3, 2022
  2. Start date: Feb 2022 to Apr 2022
    • Primary completion date: Feb 2024 to Apr 2024
    • Study completion date: Feb 2026 to Apr 2026
    • Study title expanded, about 5 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Trial Details
NCT Number NCT05197881
Lead Sponsor Varian, a Siemens Healthineers Company
Conditions
(from sponsor)		 Cervical Cancer by FIGO Stage 2018
Enrollment 125 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov